Publications
- Atezolizumab in the first-line treatment of non-small cell lung cancer - the IMpower110 trial2022 | First Faculty of Medicine
- An ocular lesion of unknown aetiology2021 | First Faculty of Medicine
- Treatment of ALK positive non-small cell lung cancer2021 | First Faculty of Medicine
- Brigatinib2021 | First Faculty of Medicine
- What approach to ALK-positive NSCLC?2020 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Targeted treatment of bronchogenic carcinoma2020 | First Faculty of Medicine
- Lorlatinib in the treatment of non-small cell lung cancer2020 | First Faculty of Medicine
- Atezolizumab in the treatment of non-small cell lung cancer patients with EGFR and ALK mutation or rearrangement2019 | First Faculty of Medicine
- Effects of Treatment with Crizotinib on Non-small Cell Lung Carcinoma with ALK Translocation in the Czech Republic2018 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové
- Diagnosing lung cancer in pulmonology centers2018 | First Faculty of Medicine, Second Faculty of Medicine
Loading network view...